drugset / Trial / NCT05263583
Sepantronium Bromide for the Treatment of High-grade B-cell Lymphoma
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a multi-center Phase 2 study to determine the safety and efficacy of sepantronium bromide (SepB) in adult patients with relapsed or refractory high-grade B-cell lymphoma
Timeline
- Start
- 2022-12-09
- Primary completion
- 2025-03-01
- Completion
- 2025-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SEPANTRONIUM | Small molecule | 3.6 mg/m2 | Intravenous |
| Subject | SEPANTRONIUM | Small molecule | 4.8 mg/m2 | Intravenous |